TAK•Takeda said new analyses show Mimrylo reduced symptoms and treatment burden in polycythemia vera. The company will present the research at the American Society of Hematology annual meeting in New Orleans on December 12-15, 2026.
Takeda said new analyses show Mimrylo reduced symptoms and treatment burden in polycythemia vera; the drug has FDA clearance for adults with the disease. The company will present research at the American Society of Hematology annual meeting in New Orleans on December 12-15, 2026. Phase 2 analyses of investigational elritercept and mezagitamab also examined responses, quality of life and platelet counts in patients with blood disorders.
